South & Central America Hyperpigmentation Disorder Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type, Condition, and End User

The South & Central America hyperpigmentation disorder treatment market was valued at US$ 887.76 million in 2022 and is expected to reach US$ 1.48 billion by 2030; it is estimated to register a CAGR of 6.6% from 2022 to 2030.

Rise in Prevalence of Melasma Fuels South & Central America Hyperpigmentation Disorder Treatment Market

Melasma, one of the most dominant hyperpigmentation conditions, is characterized by symmetrical light to dark muddy-brown macules with borders on the face, particularly the chin, upper lip, nose, forehead, and cheeks. It is prevalent among women and those with darker complexion. Malar, mandibular, and centrofacial clinical features are common in melasma. Sun exposure, hormonal variations, pregnancy, hereditary factors, cosmetics, and medicines have all been linked to the development of melasma. Various studies have estimated that the overall prevalence of melasma in the general population ranges from 1% to 50%. 55-64% of melasma cases have reported a family history of the same condition.

Pregnancy is another common cause of melasma. This condition also impacts women taking oral contraceptives and hormones. Estrogen, progesterone, and melanocyte-stimulating hormone levels normally rise during the third trimester of pregnancy, which may be a factor. According to the National Center for Biotechnology Information (NCBI) in August 2023, melasma is more common in reproductive years, and it rarely occurs before puberty; the condition occurs in 15-50% of pregnant women, and its prevalence ranges from 1.5% to 33%, depending on the population in a different region. Therefore, an upsurge in melasma prevalence triggers the demand for hyperpigmentation treatments.

South & Central America Hyperpigmentation Disorder Treatment Market Overview

The hyperpigmentation disorder treatment market in Brazil is experiencing notable growth due to the rising number of hyperpigmentation cases. According to an article published by the Journal of Skin and Stem Cell in January 2022, the prevalence of pigmented phenotypes is higher in Southeast Asian, Middle Eastern, Mediterranean, Hispanic-American, and Brazilian populations. A study based in Brazil presented in the article concluded that melasma was the third most frequent reason for skin-related consultations among 57,343 patients.

Furthermore, with the expansion of healthcare expenditure in Brazil, there is a corresponding rise in investments and resources allocated to dermatological care, including product development activities and the promotion of effective acne medications. This financial boost enhances research and development efforts, fostering the introduction of advanced formulations and treatment options in the market in the country. The improved accessibility to healthcare services and growing skincare awareness further bolsters the demand for hyperpigmentation disorder treatment across the country.

South & Central America Hyperpigmentation Disorder Treatment Market Revenue and Forecast to 2030 (US$ Million)

South & Central America Hyperpigmentation Disorder Treatment Market Segmentation

The South & Central America hyperpigmentation disorder treatment market is categorized into treatment type, condition, end user, and country.

By treatment type, the South & Central America hyperpigmentation disorder treatment market is segmented into cosmeceutical, light or laser therapy, microdermabrasion, chemical peels, cryotherapy, and others. The cosmeceutical segment held the largest share of the South & Central America hyperpigmentation disorder treatment market share in 2023.

• In terms of condition, the South & Central America hyperpigmentation disorder treatment market is segmented into melasma, solar lentigines, post-inflammatory hyperpigmentation, and others. The melasma segment held the largest share of the South & Central America hyperpigmentation disorder treatment market share in 2023.
• By end user, the South & Central America hyperpigmentation disorder treatment market is hospitals, dermatology centers, and others. The hospital segment held the largest share of the South & Central America hyperpigmentation disorder treatment market share in 2023.
• Based on country, the South & Central America hyperpigmentation disorder treatment market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil segment held the largest share of South & Central America hyperpigmentation disorder treatment market in 2023.

AbbVie Inc, Bayer AG, Galderma SA, L’OREAL S.A., Lutronic Co Ltd, Obagi Cosmeceuticals LLC, and Pierre Fabre SA are some of the leading companies operating in the South & Central America hyperpigmentation disorder treatment market.

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America hyperpigmentation disorder treatment market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the South & Central America hyperpigmentation disorder treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America hyperpigmentation disorder treatment market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.